Material Agreement (Form 8-K)

Item 1.01 Entry into a Material Definitive Agreement.

On March 6, 2026, Lixte Biotechnology Holdings, Inc., (the "Company"), Liora Technologies Europe Ltd, a subsidiary of the Company ("Liora") and Orbit Capital Inc., ("Orbit"), entered into an Amended and Restated Share Exchange Agreement with an effective date of November 21, 2025 (the A&R Agreement). The A&R Agreement amends and restates certain terms of the Share Exchange Agreement entered into among the Company, Liora and Orbit Capital on November 21, 2025 (the "Original SEA").

In connection with the Original SEA, the Company had acquired 100% of Liora and in connection therewith had issued 2,700 shares of its Series C Preferred Stock and entered into a Royalty Agreement with Orbit (the "Royalty Agreement"). On December 16, 2025, the Company and Orbit entered into a Termination Letter (the "Termination Letter"), whereby the Company and Orbit Capital terminated the Royalty Agreement. Additionally, on December 30, 2025, the Company and Orbit entered into a Share Exchange Agreement (the "Post-Closing SEA"), whereby Orbit exchanged 2,700 shares of the Company's Series C Preferred Stock for 700,000 shares of the Company's common stock and reacquired a 20% ownership interest in Liora (the "Post Closing SEA Transactions"). The Company, Liora and Orbit intended that the transactions occurring under the Original SEA, the Termination Letter and the Post-Closing SEA (collectively, the "Transaction Documents") all be given effect as if they all occurred on the date of the Original SEA. Accordingly, the Company and Orbit have entered into the A&R Agreement to clarify and consolidate the transactions contemplated by the Transaction Documents and by such interim arrangements into a single integrated agreement reflecting the parties' intent and agreed upon ownership structure.

The A&R Agreement is being filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the A&R Agreement, which is filed herewith as Exhibits 10.1.